When was Arstasis founded?

Arstasis was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Where is Arstasis located?

Arstasis is headquartered in Redwood City, United States.

How many employees does Arstasis have?

As of Jul 01, 2024, the latest employee count at Arstasis is 23.

Is Arstasis a funded company?

Arstasis is a funded company, having raised a total of $102M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 27, 2009.

When was the latest funding round of Arstasis?

Arstasis' latest funding was a $***** Series E round on Nov 13, 2013, with participation from 0 investor. Its primary sector is Cardiac and Vascular Disorders. In United States, the Cardiac and Vascular Disorders sector has seen $852M in funding in 2026 to date.

Where does Arstasis rank among its competitors?

Arstasis ranks 59th amongst 115 active competitors, of which 46 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was ivWatch, which secured $26.9M in Jan, 2024.

Who are the top competitors of Arstasis?

Arstasis' top competitors include TISSIUM, Vivasure Medical and Laminate Medical. Among them, ivWatch secured the most recent funding round in January, 2024.

Arstasis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Arstasis is a medical device co. and has developed a self-sealing femoral artery access procedure, aimed to eliminate the need for vascular closure implants. The AXERA Access Device, was launched in the U.S. in May 2011.

Website: arstasis.com
Social

Key Metrics

Founded Year

2004

Location

Redwood City, United States

Stage

Deadpooled

Total Funding

$102M in 4 rounds

Latest Funding Round

Series E, Nov 13, 2013, $*****

Investors

Ascent Biomedical Ventures

Ranked

59^th among 115 active competitors

Employee Count

23 as on Jul 01, 2024

Similar Companies

TISSIUM & 158 more

View Arstasis' full profile

Arstasis has raised a total funding of $102M over 4 rounds. Its first funding round was on Apr 27, 2009. Arstasis has 1 institutional investor.

Here is the list of recent funding rounds of Arstasis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2013	2498133	Series E	3615299	4383553	7361730	6057707
Jun 22, 2012	4195269	Series E	4269816	3323394	7541245	9537779
May 31, 2011	2568075	Series E	9675222	9897638	7595858	2412177

Access funding benchmarks and valuations. Sign up today!

View details of Arstasis's funding rounds and investors

The founders of Arstasis is Bruce Modesitt.

Here are the details of Arstasis' key team members:

Bruce Modesitt: Founder, President, and CEO of Arstasis.

View details of Arstasis's Founder profiles and Board Members

Arstasis' employee count trend

Arstasis has 23 employees as of Jul 24. Here is Arstasis's employee count trend over the years:

Uncover Arstasis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Arstasis include TISSIUM, Vivasure Medical and Laminate Medical. Here is the list of Top 10 competitors of Arstasis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	TISSIUM 2013, Paris (France), Series D	Developer of vascular sealant for open vascular surgery	$156M	Cathay Capital, BNP Paribas Developpement ... & 15 others	65/100
2nd	Vivasure Medical 2009, Galway (Ireland), Acquired	Developer of polymer implants and delivery systems	$92.1M	Fountain Healthcare Partners, Ascent Biomedical Ventures ... & 12 others	61/100
3rd	Laminate Medical 2012, Rehovot (Israel), Series C	Device to prevent AV Fistula failure by promoting their maturation and patency	$20M	Valiance Asset Management, Haisco Pharmaceutical Group ... & 25 others	52/100
4th	EKOS Corporation 1995, Bothell (United States), Acquired	Developer of a device for thrombolysis to treat pulmonary embolism	$58.8M	Hercules Capital, Mitsui & 17 others	52/100
5th	ivWatch 2010, Williamsburg (United States), Series E	Detecting Intravenous infiltration	$90.1M	757 Angels	51/100
6th	AccessClosure 2002, Mountain View (United States), Acquired	Vascular closure device	$18.7M	Industry Ventures, HealthCor Partners & 5 others	50/100
7th	Cardival Medical 2002, Santa Clara (United States), Acquired	Developer of a device for vascular access management	$169M	LKCM, Western Technology Investment & 12 others	49/100
8th	Phraxis 2008, St. Paul (Canada), Series B	Vascular access device for hemodialysis	$14.4M	-	49/100
9th	SINOMED 2007, Tianjin (China), Funding Raised	Provider of coronary stent and interventional devices	-	Qiming Venture Partners, CoStone Capital & 5 others	47/100
10th	Aziyo Biologics 2015, Silver Spring (United States), Public	Developer of regenerative medicine products for various applications	$49.6M	Deerfield, HighCape Capital & 2 others	47/100
59th	Arstasis 2004, Redwood City (United States), Deadpooled	Self-sealing artery access device	$102M	Ascent Biomedical Ventures	30/100